A robust population-based screening platform, HuScreen™, enables identification of candidates, indications and biomarkers by mouse clinical trial using a large, diverse and fully annotated PDXs

An abstract of the study by Guo et al evaluating a robust population-based screening platform, HuScreen™ which enables identification of candidates, indications and biomarkers by mouse clinical trial using a large, diverse and fully annotated PDXs is presented. In this study, they aim at building a large diverse PDX library and large-scale global industry capacity supporting multiple-center mouse clinical trial (MCT) and analyzed several MCT datasets to assess the impact of different parameters used in trial/screen process. Results, the largest diverse PDX library (>3,000 HuPrime) with full annotations (1, 3-5, 7-9) were built, that enables the simultaneous testing of large panel of different agents on hundreds of subject models. Furthermore, optimally designed and implemented HuScreen™ platform can be a powerful tool to prioritize candidates, select indications and discover predictive biomarkers, as well as repurpose drugs.